Kiniksa Pharmaceuticals Provides Corporate Update
– ARCALYST® 2023 net product revenue grew ~90% year-over-year to $233.1 million – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart Phase 2...
Stay updated with breaking news from Rheumatoid Factor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– ARCALYST® 2023 net product revenue grew ~90% year-over-year to $233.1 million – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart Phase 2...
The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new immunoassay interference blockers, K-Block™, and Mouse-Free IgG.
/PRNewswire/ -- The "Autoimmune Disease Diagnostics Market by Product (Reagents, Kits, Assays, Instruments), Test Type (ANA, CRP, ESR, Rheumatoid Factor,...
Treatment for arthritis focuses on relieving symptoms and improving joint function. One may end up trying several medications. The following can be used:
/PRNewswire/ -- The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw...